SHANDONG BOAN BIOTECH.H 1 (UJ9) - Net Assets
Based on the latest financial reports, SHANDONG BOAN BIOTECH.H 1 (UJ9) has net assets worth €2.74 Billion EUR (≈ $3.20 Billion USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€4.13 Billion ≈ $4.82 Billion USD) and total liabilities (€1.39 Billion ≈ $1.62 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Explore UJ9 cash flow conversion to assess how effectively this company generates cash.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €2.74 Billion |
| % of Total Assets | 66.41% |
| Annual Growth Rate | 15.27% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 30.56 |
SHANDONG BOAN BIOTECH.H 1 - Net Assets Trend (2021–2025)
This chart illustrates how SHANDONG BOAN BIOTECH.H 1's net assets have evolved over time, based on quarterly financial data. Also explore how large is SHANDONG BOAN BIOTECH.H 1's balance sheet for the complete picture of this company's asset base.
Annual Net Assets for SHANDONG BOAN BIOTECH.H 1 (2021–2025)
The table below shows the annual net assets of SHANDONG BOAN BIOTECH.H 1 from 2021 to 2025. For live valuation and market cap data, see how much is SHANDONG BOAN BIOTECH.H 1 worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €2.74 Billion ≈ $3.20 Billion |
+66.66% |
| 2024-12-31 | €1.64 Billion ≈ $1.92 Billion |
+24.56% |
| 2023-12-31 | €1.32 Billion ≈ $1.54 Billion |
-6.95% |
| 2022-12-31 | €1.42 Billion ≈ $1.66 Billion |
-8.59% |
| 2021-12-31 | €1.55 Billion ≈ $1.81 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to SHANDONG BOAN BIOTECH.H 1's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 37792300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €3.29 Billion | 120.22% |
| Total Equity | €2.74 Billion | 100.00% |
SHANDONG BOAN BIOTECH.H 1 Competitors by Market Cap
The table below lists competitors of SHANDONG BOAN BIOTECH.H 1 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
LASSONDE INDUST.INC. A
F:0OO
|
$448.50 Million |
|
Lavvi Empreendimentos Imobiliários S.A
SA:LAVV3
|
$448.67 Million |
|
Iteos Therapeutics Inc
NASDAQ:ITOS
|
$448.68 Million |
|
Studio City International Holdings Ltd
NYSE:MSC
|
$448.73 Million |
|
Acacia Research Corporation
NASDAQ:ACTG
|
$448.17 Million |
|
Unipar Carbocloro S.A
SA:UNIP3
|
$448.12 Million |
|
Alandsbanken Abp B
HE:ALBBV
|
$448.11 Million |
|
CNFC Overseas Fishery Co Ltd
SHE:000798
|
$448.10 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in SHANDONG BOAN BIOTECH.H 1's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,644,038,000 to 2,739,887,000, a change of 1,095,849,000 (66.7%).
- Net income of 7,144,000 contributed positively to equity growth.
- New share issuances of 1,075,535,000 increased equity.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €7.14 Million | +0.26% |
| Share Issuances | €1.08 Billion | +39.25% |
| Other Changes | €13.17 Million | +0.48% |
| Total Change | €- | 66.66% |
Book Value vs Market Value Analysis
This analysis compares SHANDONG BOAN BIOTECH.H 1's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.15x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €3.05 | €0.64 | x |
| 2022-12-31 | €2.79 | €0.64 | x |
| 2023-12-31 | €2.59 | €0.64 | x |
| 2024-12-31 | €3.07 | €0.64 | x |
| 2025-12-31 | €4.40 | €0.64 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently SHANDONG BOAN BIOTECH.H 1 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.26%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.91%
- • Asset Turnover: 0.19x
- • Equity Multiplier: 1.51x
- Recent ROE (0.26%) is above the historical average (-8.45%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -14.53% | -142.04% | 0.08x | 1.36x | €-380.59 Million |
| 2022 | -23.39% | -64.30% | 0.23x | 1.55x | €-473.59 Million |
| 2023 | -9.04% | -19.31% | 0.27x | 1.76x | €-251.36 Million |
| 2024 | 4.45% | 10.08% | 0.25x | 1.73x | €-91.21 Million |
| 2025 | 0.26% | 0.91% | 0.19x | 1.51x | €-266.84 Million |
Industry Comparison
This section compares SHANDONG BOAN BIOTECH.H 1's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $223,512,703
- Average return on equity (ROE) among peers: -29.10%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| SHANDONG BOAN BIOTECH.H 1 (UJ9) | €2.74 Billion | -14.53% | 0.51x | $448.41 Million |
| PROQR THERAPEUTICS EO-04 (0PQ) | $49.37 Million | -85.44% | 1.28x | $142.34 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $41.28 Million | -56.73% | 0.18x | $161.62 Million |
| Theravance Biopharma Inc (0TB) | $-303.75 Million | 0.00% | 0.00x | $823.46 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $715.33 Million | -51.14% | 0.23x | $212.27 Million |
| PreveCeutical Medical Inc (18H) | $-4.49 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $344.93 Million | -8.14% | 0.08x | $41.67 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $518.36 Million | -39.43% | 0.23x | $1.14 Billion |
| BIOCURE TECHNOLOGY INC. (1WH) | $1.34 Million | -19.58% | 0.49x | $960.84K |
| ZAI LAB LTD0000006 (1ZLB) | $840.90 Million | -30.57% | 0.41x | $1.82 Billion |
| BioNTech SE (22UA) | $31.86 Million | 0.00% | 11.24x | $20.05 Billion |
About SHANDONG BOAN BIOTECH.H 1
Shandong Boan Biotechnology Co., Ltd., a biopharmaceutical company, develops, manufactures, and markets biologics in Mainland China. The company offers Boyounuo (BA1101), an anti-VEGF humanized monoclonal antibody injection for mCRC, advanced metastatic or recurrent non-small cell lung cancer, recurrent glioblastoma, epithelial ovarian, fallopian tube, primary peritoneal cancer, cervical cancer, … Read more